Precision Biosciences Inc
NASDAQ:DTIL 11:17:23 AM EDT
Regulatory, Earnings Announcements
Precision Biosciences Reports Positive Interim Results From Pbcar0191 Phase 1/2A Trial In Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (Nhl) And R/R B-Cell Acute Lymphoblastic Leukemia (B-All)
Published: 12/04/2020 13:24 GMT
Precision Biosciences Inc (DTIL) - Precision Biosciences Reports Positive Interim Results From Pbcar0191 Phase 1/2a Trial in Relapsed/refractory (r/r) Non-hodgkin Lymphoma (nhl) and R/r B-cell Acute Lymphoblastic Leukemia (b-all).
Precision Biosciences Reports Positive Interim Results From Pbcar0191 Phase 1/2a Trial in Relapsed/refractory (r/r) Non-hodgkin Lymphoma (nhl) and R/r B-cell Acute Lymphoblastic Leukemia (b-all).
Precision Biosciences Inc - Pbcar0191 Demonstrated Longest Durability of Response to 11 Months in B-all.
Precision Biosciences Inc - Pbcar0191 With Enhanced Lymphodepletion Resulted Inobjective Response Rate (orr) of 83% (5/6) in Nhl and B-all.
Precision Biosciences - As of Nov 16, 27 Patients Including 16 Patients With Aggressive Nhl, 11 Patients With Aggressive B-all Were Enrolled and Evaluated.
Precision Biosciences - One Nhl Patient Who Was Treated With Pbcar0191 and Eld Had Previously Received Nine Prior Lines of Therapy Before Entering Trial.
Precision Biosciences Inc - the Nhl Patient Who Was Treated With Pbcar0191 and Eld Died at Day 42 With Grade 5 Sepsis.
Precision Biosciences Inc - Patient Who Had Received 9 Prior Lines of Therapy Before Entering Trial, Presented With Persistent Cytopenias at Baseline.
Precision Biosciences Inc - Expect to Move Pbcar19b Into Clinic in 2021.
Precision Biosciences Reports Positive Interim Results From Pbcar0191 Phase 1/2a Trial in Relapsed/refractory (r/r) Non-hodgkin Lymphoma (nhl) and R/r B-cell Acute Lymphoblastic Leukemia (b-all).
Precision Biosciences Inc - Pbcar0191 Demonstrated Longest Durability of Response to 11 Months in B-all.
Precision Biosciences Inc - Pbcar0191 With Enhanced Lymphodepletion Resulted Inobjective Response Rate (orr) of 83% (5/6) in Nhl and B-all.
Precision Biosciences - As of Nov 16, 27 Patients Including 16 Patients With Aggressive Nhl, 11 Patients With Aggressive B-all Were Enrolled and Evaluated.
Precision Biosciences - One Nhl Patient Who Was Treated With Pbcar0191 and Eld Had Previously Received Nine Prior Lines of Therapy Before Entering Trial.
Precision Biosciences Inc - the Nhl Patient Who Was Treated With Pbcar0191 and Eld Died at Day 42 With Grade 5 Sepsis.
Precision Biosciences Inc - Patient Who Had Received 9 Prior Lines of Therapy Before Entering Trial, Presented With Persistent Cytopenias at Baseline.
Precision Biosciences Inc - Expect to Move Pbcar19b Into Clinic in 2021.
Revenue is expected to be $5.68 Million
Adjusted EPS is expected to be -$0.24
Next Quarter Revenue Guidance is expected to be $6.18 Million
Next Quarter EPS Guidance is expected to be -$0.24
More details on our Analysts Page.
Adjusted EPS is expected to be -$0.24
Next Quarter Revenue Guidance is expected to be $6.18 Million
Next Quarter EPS Guidance is expected to be -$0.24
More details on our Analysts Page.